BioSpace News Archive

Charles River Laboratories International, Inc. announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus -based gene therapy programs.

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults.

Rapport Therapeutics, Inc. announced the appointment of Terry-Ann Burrell to its Board of Directors.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 first quarter ended December 31, 2023, before the opening of the market on Friday, February 2, 2024.

Agilent Technologies Inc. announced the release of a new automated parallel capillary electrophoresis system for protein analysis – the Agilent ProteoAnalyzer system – at the 23rd Annual PepTalk Conference, being held January 16-19 in San Diego.

PolTREG S.A. announced it received a Notice of Allowance from the United States Patent and Trademark Office, covering the manufacturing of T-regulatory cells to treat Type-1 Diabetes, and ways the therapy is administered.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has updated the label for Dupixent® in atopic dermatitis, adding efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter and full year 2023 before the market opens on Thursday, February 15, 2024.

Allakos Inc. today announced topline data from its phase 2 clinical trial in patients with atopic dermatitis (ATLAS) and from its Phase 2b clinical trial in patients with chronic spontaneous urticaria (MAVERICK).

Satellos Bioscience Inc. is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (“TSX”) to graduate from the TSX Venture Exchange (the “TSXV”) and to list its common shares (the “Common Shares”) on the TSX.